Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06352502
Other study ID # 202112-28
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 28, 2022
Est. completion date September 30, 2024

Study information

Verified date April 2024
Source Tang-Du Hospital
Contact Haichuan Su, PhD
Phone 18629190366
Email such@fmmu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M mutation positive NSCLC. This study aims to investigate the efficacy and safety of furmonertinib in the treatment of EGFR-sensitive mutation positive NSCLC patients with brain metastasis.


Description:

This study aims to prospectively observe the efficacy and safety of furmonertinib in the treatment of EGFR-sensitive mutation positive NSCLC patients with brain metastasis and will recruit about 30 patients in China. Furmonertinib (AST2818) is a brain penetrant third generation EGFR TKI. In preclinical studies, the concentration of furmonertinib and its main active metabolite in the brain was higher than that in the plasma, indicating that furmonertinib had the potential to treat CNS metastases. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily in patients with EGFR T790M mutated NSCLC, the median CNS PFS was 11.6 months and 19.3 months in the 80 mg and 160 mg orally once daily group, and the CNS ORR was 65% and 85% in the 80 mg and 160 mg group. This study will enroll the EGFR-sensitive mutation positive NSCLC patients with brain metastasis who are treated by furmonertinib, and the efficacy and safety data will be recorded.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. at least 18 years of age; 2. Histologically or cytologically confirmed metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC); 3. Patient with EGFR 19Del or L858R mutation diagnosed histologically or cytologically.( EGFR L858R or Del 19 with/without T790M ) 4. Imaging (MR/CT) confirmed untreated brain metastases before Furmonertinib initiation; 5. Organ function is compatible with oral Furmonertinib therapy (investigator determination based on real-world practice); 6. Life expectancy =12 weeks before Fumonertinib initiation; 7. ECOG PS of 0 to 2; 8. Sign the informed consent form. Exclusion Criteria: 1. Any Third-Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) before Furmonertinib initiation; 2. Known hypersensitivity to Furmonertinib or its excipient components; 3. Simultaneous systemic chemotherapy or WBI; 4. The time from the treatment with any other investigational product or its analogue before Furmonertinib initiation does not exceed 5 half-lives of the drug or 14 days, whichever is longer; 5. Any evidence of severe or uncontrolled systemic diseases; 6. Presence of any disease that may strongly interfere with oral drug absorption; presence of any factor that contributes to QTc prolongation or increased risk of arrhythmia; presence of interstitial pneumonitis.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Furmonertinib
Patients treated with Furmonertinib mesilate tablets orally

Locations

Country Name City State
China Tangdu Hopspital Xi'an Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Tang-Du Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intracranial Objective response rate Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) using Investigator assessments, is defined as the number (%) of patients with CNS lesion response of Complete Response or Partial Response, will be assessed up to 2 years. Data obtained up until progression, or the last evaluable assessment in the absence of progression, will be assessed up to 2 years.
Primary Intracranial Disease Control Rate The percentage of subjects who have a best CNS lesion response of Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by the Investigator, will be assessed up to 2 years. Data obtained up until progression, or the last evaluable assessment in the absence of progression, will be assessed up to 2 years.
Primary Intracranial progression-free survival Intracranial progression-free survival (PFS) analysis based on investigator assessment and will be assessed up to 3 years. Intracranial progression-free survival (PFS) analysis based on investigator assessment and will be assessed up to 3 years.
Secondary Progression-free survival Progression-free survival (PFS) is defined as the time from first dose of Furmonertinib recorded until the date of disease progression based on investigator assessment. Progression-free survival (PFS) analysis based on investigator assessment per RECIST 1.1, and will be assessed up to 2 years.
Secondary Overall Survival Overall survival is defined as the time from beginning of furmonertinib treatment until death due to any cause and will be assessed up to 3 years. The time from beginning of furmonertinib treatment until death due to any cause and will be assessed up to 3 years.
Secondary Safety/Adverse event Incidence of Adverse Events (AEs): Incidence, severity and seriousness of adverse events, incidence of serious adverse events (SAEs), which usually be graded by CTCAE v5.0 based on current clinical practice. From the recorded first dose of Furmonertinib to 4 weeks after the recorded last dose of Furmonertinib
See also
  Status Clinical Trial Phase
Recruiting NCT04989322 - Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC Phase 2
Recruiting NCT03349203 - Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT05998993 - Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) N/A
Recruiting NCT05033691 - A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases N/A
Recruiting NCT05256290 - Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Completed NCT04640870 - The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib
Active, not recruiting NCT04862780 - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Phase 1/Phase 2
Not yet recruiting NCT05110950 - Endobronchial Ultrasound Needle Aspiration With and Without Suction N/A
Completed NCT04965701 - First Line Osimertinib in the Real World: an Inter-regional Prospective Study
Terminated NCT05153408 - (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Phase 1
Not yet recruiting NCT05132985 - Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma Phase 2
Recruiting NCT04504071 - Dacomitinib in Lung Cancer With Uncommon EGFR Mutations Phase 2
Recruiting NCT06109558 - The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC Phase 1/Phase 2
Recruiting NCT05165355 - Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma Phase 2
Recruiting NCT06207292 - Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer N/A
Recruiting NCT05573373 - Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer Phase 1
Recruiting NCT03749213 - Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer Phase 2
Recruiting NCT05263947 - Bevacizumab Combined With Double Dose Icotinib in Patients With EGFR Exon 21-L858R Mutation Phase 2
Not yet recruiting NCT06287593 - The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC N/A